SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Keane Robert S

(Last) (First) (Middle)
CIMPRESS N.V.
BUILDING D, XEROX TECHNOLOGY PARK

(Street)
DUNDALK, COUNTY LOUTH, IRELAND

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CIMPRESS N.V. [ CMPR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CEO, Chairman
3. Date of Earliest Transaction (Month/Day/Year)
02/15/2019
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Performance Share Units $109.35(1) 02/15/2019 A 349 (2) 02/15/2029 Ordinary Shares 349 $0 349 D
Performance Share Units $109.35(1) 02/15/2019 A 1,143 (3) 02/15/2029 Ordinary Shares 1,143 $0 1,143 D
Performance Share Units $109.35(1) 02/15/2019 A 7,116 (4) 02/15/2029 Ordinary Shares 7,116 $0 7,116 D
Explanation of Responses:
1. This dollar amount is the three-year moving average (3YMA) on the date of grant, which is the baseline against which the compound annual growth rate (CAGR) of the 3YMA will be measured.
2. Each performance share unit (PSU) represents a right to receive between 0 and 2.5 Cimpress ordinary shares upon the satisfaction of both (A) service-based vesting and (B) performance conditions relating to the CAGR of the 3YMA. The service-based vesting condition is that 100% of the PSUs vest on June 30, 2019 so long as the reporting person continues to be an eligible participant under Cimpress' 2016 Performance Incentive Plan on the vesting date. If the 3YMA CAGR equals or exceeds 11% on any of the sixth through tenth anniversaries of the grant date then the reporting person is entitled to receive a distribution of up to 2.5 Cimpress ordinary shares for each vested PSU on a sliding scale based on the actual CAGR performance.
3. Each PSU represents a right to receive between 0 and 2.5 Cimpress ordinary shares upon the satisfaction of both (A) service-based vesting and (B) performance conditions relating to the CAGR of the 3YMA. The service-based vesting condition is that 25% of the original number of PSUs vest on each November 12 of 2019 through 2022 so long as the reporting person continues to be an eligible participant under Cimpress' 2016 Performance Incentive Plan on such vesting date. If the 3YMA CAGR equals or exceeds 11% on any of the sixth through tenth anniversaries of the grant date then the reporting person is entitled to receive a distribution of up to 2.5 Cimpress ordinary shares for each vested PSU on a sliding scale based on the actual CAGR performance.
4. Each PSU represents a right to receive between 0 and 2.5 Cimpress ordinary shares upon the satisfaction of both (A) service-based vesting and (B) performance conditions relating to the CAGR of the 3YMA. The service-based vesting condition is that 50% of the original number of PSUs vest on March 31, 2019 and the remaining 50% vest on June 30, 2019 so long as the reporting person continues to be an eligible participant under Cimpress' 2016 Performance Incentive Plan on such vesting date. If the 3YMA CAGR equals or exceeds 11% on any of the sixth through tenth anniversaries of the grant date then the reporting person is entitled to receive a distribution of up to 2.5 Cimpress ordinary shares for each vested PSU on a sliding scale based on the actual CAGR performance.
Remarks:
/s/Kathryn L. Leach, as attorney-in fact-for Robert Keane 02/19/2019
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
CIMPRESS N.V.
LIMITED POWER OF ATTORNEY
FOR SECTION 16 REPORTING OBLIGATIONS
Know all by these presents, that the undersigned hereby makes, constitutes 
and appoints each of Matthew Walsh, Kathryn Leach, and Sean E. Quinn 
signing singly and each acting individually, as the undersigned's true and 
lawful attorney-in-fact with full power and authority as hereinafter 
described to:
(1) execute for and on behalf of the undersigned, in the undersigned's 
capacity as an executive officer and/or director of Cimpress N.V. (the 
Company), Form ID and Forms 3, 4, and 5 (including any amendments 
thereto) in accordance with Section 16(a) of the United States Securities 
Exchange Act of 1934 and the rules thereunder (the Exchange Act);
(2) execute for and on behalf of the undersigned, in the undersigned's 
capacity as an executive officer and/or director of the Company such forms 
as the Autoriteit Financiele Markten in the Netherlands (AFM) or other 
Dutch authorities or laws may require;
(3) do and perform any and all acts for and on behalf of the undersigned 
which may be necessary or desirable to prepare, complete and execute any 
such Form ID, Form 3, 4, or 5 or AFM form, prepare, complete and 
execute any amendment or amendments thereto, and timely deliver
 and file 
such form with the United States Securities and Exchange Commission, 
AFM, and any stock exchange or similar authority;
(4) seek or obtain, as the undersigned's representative and on the 
undersigned's behalf, information regarding transactions in the Company's 
securities from any third party, including brokers, employee benefit plan 
administrators and trustees, and the undersigned hereby authorizes any 
such person to release any such information to such attorney-in-fact and 
approves and ratifies any such release of information; and
(5) take any other action of any type whatsoever in connection with the 
foregoing which, in the opinion of such attorney-in-fact, may be of benefit 
to, in the best interest of, or legally required by, the undersigned, it being 
understood that the documents executed by such attorney-in-fact on behalf 
of the undersigned pursuant to this Power of Attorney shall be in such form 
and shall contain such terms and conditions as such attorney-in-fact may 
approve in such attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and 
authority to do and perform any and every act and thing whatsoever 
requisite, necessary, or proper to be done in the exercise of any of the rights 
and powers herein granted, as fully to all intents and purposes as the 
undersigned might or could do if personally present, with full power of 
substitution or revocation, hereby ratifying and confirming all that such 
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall 
lawfully do or cause to be done by virtue of this power of attorney and the 
rights and powers herein granted. The undersigned acknowledges that the 
foregoing attorneys-in-fact, in serving in such capacity at the request of the 
undersigned, are not assuming nor relieving, nor is the Company assuming 
nor relieving, any of the undersigned's responsibilities to comply with 
Section 16 of the Exchange Act or applicable Dutch securities laws. The 
undersigned acknowledges that neither the Company nor the foregoing 
attorneys-in-fact assume (i) any liability for the undersigned's responsibility 
to comply with the requirements of the Exchange Act or applicable Dutch 
securities laws, (ii) any liability of the undersigned for any failure to 
comply with such requirements, or (iii) any obligation or liability of the 
undersigned for profit disgorgement under Section 16(b) of the Exchange 
Act or Dutch securities laws.
This Power of Attorney shall remain in full force and effect until the 
undersigned is no longer required to file Forms 3, 4, and 5 or AFM forms 
with respect to the undersigned's holdings of and transactions in securities 
issued by the Company, unless earlier revoked by the undersigned in a 
signed writing delivered to the foregoing attorneys-in-fact. This Power of 
Attorney supersedes and revokes all previously signed powers of attorney 
of the undersigned that grant authority to the Companys personnel with 
respect to Form ID, Forms 3, 4 and 5, AFM forms, and other Section 16 
and Dutch law compliance matters relating to the Company.
IN WITNESS WHEREOF, the undersigned has caused this Power of 
Attorney to be executed as of this 4th day of February, 2019.
/s/Robert Keane
Signature


Robert Keane            
Print Name